Q-omics provides the consensus-scored TLR12P profile across patient tissues and cancer cell-line models. TLR12P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TLR12P is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TLR12P RNA expression shows 9,933 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where TLR12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLR12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLR12P survival associations across molecular data types. TLR12P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLR12P RNA expression–survival associations across cancer types. High TLR12P expression shows unfavorable associations in UVM, THCA and LUAD, but favorable associations in KIRC, KIRP and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify UVM as the clearest survival context for TLR12P RNA expression.
This table summarizes TLR12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TLR12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLR12P shows lower tumor expression in HNSC, COAD and PRAD and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher TLR12P RNA expression in tumor versus normal tissue (log2 FC = +0.084, t-test p < 0.001).
This table shows molecular features associated with TLR12P in patient tissues and cancer cell lines. In patient samples, TLR12P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
